Regeneron Pharmaceuticals, Inc. $REGN Stock Position Cut by Greenleaf Trust

Key Points

• Greenleaf Trust has reduced its stake in Regeneron Pharmaceuticals by 24.3%, selling 464 shares and now owning a total of 1,448 shares valued at approximately $760,000.
• Regeneron Pharmaceuticals reported strong quarterly earnings, with an earnings per share (EPS) of $12.89, exceeding analysts' expectations of $8.43, alongside a revenue of $3.68 billion.
• The company announced a quarterly dividend of $0.88, which represents an annualized yield of 0.6% and indicates a low dividend payout ratio of 8.87%.

Greenleaf Trust lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 24.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,448 shares of the biopharmaceutical company's stock after selling 464 shares during the period. Greenleaf Trust's holdings in Regeneron Pharmaceuticals were worth $760,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of REGN. Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $343,764,000. Pacer Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after purchasing an additional 303,785 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $600.00 on Friday. The company has a 50 day simple moving average of $571.38 and a 200-day simple moving average of $568.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market capitalization of $63.59 billion, a price-to-earnings ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,038.81.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.56 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.